Vera Therapeutics
VERA
30.25
+0.83
+2.82%
Vera Therapeutics
US · VERA
#2739 by market cap
Listed 2021
30.25
+0.83
+2.82%
Live - 5344 symbols - heartbeat 190s ago
· 2026-10-08 04:00
Pre-market
30.25
0.00%
After-hours
30.00
-0.83%
- Market cap
- 2.18B
- P/E (TTM)i
- -5.15
- P/Bi
- 5.35
- EPSi
- -4.66
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on VERA?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 11 analysts
Buy
Avg price target
77.22 +155.3%
Price target rangecurrent 30.25
Low34.00
Avg77.22
High100.00
Buy 91%
Hold 9%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-01 | H.C. Wainwright | -- | BUY | 90.00 |
| 2026-09-16 | Wedbush | -- | HOLD | 34.00 |
| 2026-09-15 | Wells Fargo | -- | BUY | 70.00 |
| 2026-09-15 | LifeSci Capital | -- | BUY | 90.00 |
| 2026-09-15 | Raymond James | -- | BUY | -- |
| 2026-09-15 | BofA Securities | -- | BUY | 66.00 |
| 2026-09-15 | J.P. Morgan | -- | BUY | -- |
| 2026-09-08 | J.P. Morgan | -- | BUY | 83.00 |
| 2026-08-31 | TD Cowen | -- | BUY | 78.00 |
| 2026-08-17 | Wedbush | -- | HOLD | 34.00 |
| 2026-08-17 | J.P. Morgan | -- | BUY | 76.00 |
| 2026-08-14 | BofA Securities | -- | BUY | 66.00 |
| 2026-08-14 | Guggenheim | -- | BUY | 76.00 |
| 2026-08-12 | Wells Fargo | -- | BUY | 70.00 |
| 2026-08-12 | H.C. Wainwright | -- | BUY | 90.00 |
| 2026-08-11 | TD Cowen | -- | BUY | 78.00 |
| 2026-08-11 | LifeSci Capital | -- | BUY | 90.00 |
| 2026-08-11 | Raymond James | -- | BUY | 84.00 |
| 2026-08-11 | Wedbush | -- | HOLD | 34.00 |
| 2026-08-10 | Cantor Fitzgerald | -- | BUY | 100.00 |
| 2026-08-10 | BofA Securities | -- | BUY | 66.00 |
| 2026-08-04 | Wells Fargo | -- | BUY | 70.00 |
| 2026-07-13 | Wedbush | -- | HOLD | 43.00 |
| 2026-07-11 | LifeSci Capital | -- | BUY | 90.00 |
| 2026-07-09 | Evercore | -- | BUY | 91.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 04:00:01 · For reference only, not investment advice and not tailored to your situation.